Improved survival in patients with lung only recurrence after surgical resection of pancreatic ductal adenocarcinoma.

Authors

null

Michael S. May

Columbia University Medical Center, New York, NY

Michael S. May , Alissa Michel , Tristan Lee , Winston Wong , Jacob K.R. Jamison , David Manrique , Samuel M Pan , Jianhua Hu , Rachael A Safyan , Alexander Raufi , Michael Kluger , Susan Elaine Bates , John A. Chabot , Gulam Abbas Manji

Organizations

Columbia University Medical Center, New York, NY, Columbia University Irving Medical Center, New York, NY, Memorial Sloan Kettering Cancer Center, New York City, NY, Columbia University Irving Medical Center, New York,, NY, Lifespan Cancer Institute, Providence, RI, Columbia University Medical Center and New York-Presbyterian Hospital, New York, NY, Columbia University Herbert Irving Comprehensive Cancer Center, New York, NY

Research Funding

No funding received

Background: Recurrence rates after resection of pancreatic ductal adenocarcinoma (PDA) can be up to 80%. Prior data suggests that initial site of recurrence influences prognosis. This study aims to compare survival of patients (pts) with resected PDA by initial site of recurrence. Methods: We retrospectively reviewed the demographics, treatments, recurrence and survival of 717 pts with PDA who underwent resection at Columbia University Irving Medical Center from 2011 to 2020 and were part of a tumor registry. Analyses were performed using Kaplan-Meier and paired T-tests. Results: Of 717 pts with resected PDA, 320 had confirmed recurrence. Median age at diagnosis was 67 years (yrs). Among pts with a single initial recurrence site, 36 recurred in lung, 97 in liver, 95 locally, and 23 in peritoneum. 58 pts had initial recurrence at 2 or more sites. Neoadjuvant treatment had been administered in 42%, 36%, 40%, 35%, and 22% of pts with lung, liver, local, peritoneal, and multiple sites at initial recurrence, respectively (p=0.21). Adjuvant treatment had been administered in 72%, 69%, 76%, 70%, and 72% of pts with lung, liver, local, peritoneal, and multiple sites at initial recurrence, respectively (p=0.88). Pts with initial lung recurrence had a significantly longer median overall survival (mOS), 4.39 yrs, compared to initial recurrence in the liver (1.98 yrs, p=0.02), peritoneum (2.19 yrs, p=0.0002), and at multiple sites (2.66 yrs, p=0.03). A significantly longer time from diagnosis to recurrence was observed in pts who had initial lung recurrence, compared to pts who had initial hepatic, peritoneal or multiple site recurrences. Pts with initial lung recurrence had a significantly longer time from first recurrence to death compared to pts with initial peritoneal recurrence. See Table for summary. Conclusions: Pts with resected PDA with initial pulmonary recurrence experience improved survival compared to those who recur at other distinct or multiple sites. The underlying pathways contributing to this improved survival need to be investigated further.

Initial recurrence
N=

360
mOS from time of pathological diagnosis, yrs (95% CI) [p-value]
mOS from time of surgery, yrs (95% CI) [p-value]
Median time from diagnosis to first recurrence, yrs [p-value]
Median time from first recurrence to death, yrs [p-value]
Lung only
36 (11%)
4.39 (3.34-5.24)
4.18 (3.34-5.19)
2.01
1.34
Liver only
97 (30%)
1.98 (1.74-2.53) [0.02]
1.76 (1.49-2.30) [0.01]
0.90 [0.00009]
0.94 [0.3]
Local only
95 (30%)
3.15 (2.68-4.11) [0.30]
2.76 (2.34-4.04) [0.40]
1.20 [0.05]
1.45 [0.7]
Peritoneal only
23 (7%)
2.19 (1.51-2.86) [0.0002]
2.10 (0.93-2.36) [0.0001]
1.08 [0.00009]
0.82 [0.01]
Multiple Sites
58 (18%)
2.66 (2.05-3.42) [0.03]
2.34 (1.53-3.38) [0.04]
1.05 [0.0005]
0.877 [0.4]

p-values are for comparisons with lung-only recurrence

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2022 ASCO Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract

Track

Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer

Sub Track

Tumor Biology, Biomarkers, and Pathology

DOI

10.1200/JCO.2022.40.4_suppl.608

Abstract #

608

Poster Bd #

Online Only

Abstract Disclosures

Similar Abstracts

First Author: Jaewoo Kwon

First Author: Eileen Mary O'Reilly

First Author: Jeffrey How